No Data
No Data
No Data
Mendus Publishes Prospectus Regarding Previously Announced Rights Issue and Directed Issue
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA,
Mendus AB: Report From the Extraordinary General Meeting of Mendus AB (Publ) on 10 July 2023
At the extraordinary general meeting (the "EGM") of Mendus AB (publ), reg. no. 556629-1786, (the "Company"), on 10 July 2023 the EGM adopted, inter alia, the following resolutions. For more detailed i
Mendus Receives ATMP Certificate From European Medicines Agency Supporting Its Lead Pipeline Program Vididencel
POSITIVE RECOMMENDATION BY COMMITTEE FOR ADVANCED THERAPIES CONFIRMS QUALITY OF THE MANUFACTURING PROCESS AND PRECLINICAL DATA SUBMITTED Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company
Invitation to Mendus' Update on Vididencel Program as Online and On-site Events on June 27th, 2023
Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will provide an update on its lead program vididencel on Tuesday, June 27, 2023.
Mendus Presents Comprehensive ADVANCE II Immunomonitoring Data at the EHA Annual Meeting 2023
VIDIDENCEL ADMINISTRATION LED TO BROAD IMMUNE ACTIVATION WITH INNATE AND ADAPTIVE IMMUNE RESPONSES OBSERVED Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies a
Eurozone's Q1 Recession Weigh on Most EU Markets Thursday
The eurozone's recession in Q1, coupled with talks of an unlikely Q2 rebound, weighed on most European markets Thursday. Upon closing, the Stoxx Europe 600 was down 0.2%, London's FTSE 100 fell 0.32%,
No Data